Plotting a path to
high-quality care in diabetes
This year, the All-Ireland conference brings you the latest thinking and practical advice on diabetes in the primary care setting, and will be doing so in a new virtual format. Covering a broad range of topics, the speakers will highlight what new initiatives and changes mean for you in your everyday practice.The mix of lectures from leading healthcare professionals and interactive practical workshops will enable you – whatever your role in the primary care diabetes team – to come away having consolidated and built on your knowledge. You will also be able to work through the online CPD/CME templates throughout the day that you can take away to add to your personal development portfolio, all aimed at helping you put what you learn into practice.
We hope you will join us, virtually, for what is sure to be another invaluable event for your professional development.
Irish Representatives of the PCDS
Joanne Lowe, Community Diabetes Nurse Specialist, Co WicklowLisa Devine, GP, Co. Wicklow
Why attend? This fast-paced, interactive conference combines latest clinical guidance, research, case studies and hot topics in diabetes, including lessons learned from COVID-19 and much more.
Ask the experts your burning questions through the LIVE Q&A at the end of each session
Log on anytime during the day from the comfort of your own home to view the sessions
Don’t worry if you miss something, all of the content will be available on-demand
Claim 5 CPD/CME points points for the full-day virtual conference
The agenda
is still being confirmed for this conference,
please check back for updates.
Agenda
21 November 2020
09.00 - 09.10
Chair’s introduction
Joanne Lowe
09.10 - 09.40
What has COVID-19 taught us?
- Lessons for diabetes care
- What we can expect in the coming months
15 minute break
09.55 - 10.25
Symposia
15 minute break
10.40 - 11.10
New ways of working post-COVID-19 – performing remote reviews
- The impact of COVID-19 on the provision of routine diabetes reviews in primary care
- Delivering reviews in a way that minimises face-to-face contact – the priorities, processes and practicalities of remote working
- What works well and what improvements can we make?
15 minute break
11.25 - 12.05
‘In Practice’ masterclasses
Rotation 1
1. Injectables
2. Discover diabetes
3. Podiatry
15 minute break
12.20 - 13.00
Rotation 2
1. Injectables
2. Discover diabetes
3. Podiatry
15 minute break
13.15 - 13.45
Vulnerable groups in diabetes
- What we can do to improve access to care for vulnerable groups
- Interview style Q&A session
15 minute break
14.00 - 14.30
Symposia
15 minute break
14.45 - 15.15
Diabetes distilled Emerging evidence from the weeks and months before the conference
15.15 - 15.25
Chair’s concluding remarks
Joanne Lowe
A full-day virtual conference
21 November 2020 from 9am
Including a LIVE Q&A after every session
Speakers
Heather Bell, GP
Nigel Campbell
GP, Lisburn
Hamish Courtney
Consultant Diabetologist, Belfast
Mark Davies
Consultant Clinical Psychologist, Belfast
Su Down
Diabetes Nurse Consultant, Somerset
Kevin Fernando
GPwSI in Diabetes and Medical Education, North Berwick
Lesley Hamilton
Diabetes Network Manager, Western Trust
Rose Stewart
Conference
Sponsors
GOLD SPONSORS
AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
AstraZeneca has five different sites in the UK, where approximately 6,500 employees work in research and development, manufacturing, supply, sales and marketing. We supply over 40 different medicines to the NHS, helping to treat approximately one million patients with serious diseases. The UK is also an important location for AstraZeneca’s clinical trials; in 2017 there were 191 AZ and Medimmune clinical trials at 340 sites in the UK, involving 8,747 patients. For more information, please visit www.astrazeneca.co.uk.
Eli Lilly and Company Ltd
Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today, we are building upon this heritage by working to meet the diverse needs of people living with diabetes and those who care for them. Through research and collaboration, a wide range of therapies, and a continued determination to provide real solutions—from medicines to support programs and more—we strive to make life better for all those affected by diabetes around the world. For more information, visit www.lillydiabetes.co.uk
SILVER SPONSORS
Napp Pharmaceuticals Limited
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. We strive to offer new medicines and initiatives that support the NHS in delivering effective, high-quality, sustainable healthcare for the benefit of patients
Masterclass sponsor
Abbott’s Diabetes Care Division
Abbott’s diabetes care division is a global leader in glucose monitoring systems. We are dedicated to helping people manage their diabetes and achieve their best health outcomes with innovative technology, such as the FreeStyle Libre system, allowing patients to monitor their glucose with a quick and easy scan. For more information, such as how the FreeStyle Libre system and our digital health tools support healthcare professionals and their patients visit www.freestylediabetes.co.uk
BRONZE SPONSORS
Boehringer Ingelheim and Lilly Diabetes Alliance
Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic conditions: diabetes, haemophilia, growth disorders and obesity.
Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Every day, millions of people all over the world rely on our products, which are manufactured in nine countries.
Novo Nordisk has a unique ownership structure, with two-thirds of Novo Nordisk’s shares controlled by the Novo Nordisk Foundation. The objective of the Foundation is to provide a stable basis for the commercial and research activities of Novo Nordisk and support scientific, humanitarian and social purposes.
As the acknowledged leader in diabetes care, we work to prevent, treat and ultimately cure this increasingly onerous disease. Over the past 90 years, our researchers have pioneered many breakthroughs in its management, and today, our determination to help these people is stronger than ever.
Novo Nordisk also holds leading positions in the management of bleeding disorders, growth hormone treatment and hormone replacement therapy. We are currently researching into novel delivery systems and autoimmune and chronic inflammatory diseases, using technologies such as translational immunology and monoclonal antibodies.
